Bone Mineral Density and Lipid Changes During 5 Years of Follow-up in a Study of Prevention of Breast Cancer with Toremifene in Healthy, High-risk Pre- and Post-menopausal Women

2005 ◽  
Vol 93 (3) ◽  
pp. 277-287 ◽  
Author(s):  
R. Erkkola ◽  
L. Mattila ◽  
T. Powles ◽  
J. Heikkinen ◽  
B. Toivola ◽  
...  
2016 ◽  
Author(s):  
Fernando Blanco-Rodriguez ◽  
Nicole Ellis-Infante ◽  
Victor Lopez-Rivas ◽  
Sherlin May-Kim ◽  
Charlotte Pickett ◽  
...  

Author(s):  
Glauber Dallanezi ◽  
Beatriz Freire ◽  
Eliana Nahás ◽  
Jorge Nahás-Neto ◽  
José Corrente ◽  
...  

Maturitas ◽  
2008 ◽  
Vol 60 (3-4) ◽  
pp. 244-247 ◽  
Author(s):  
Akiko Kuwahata ◽  
Yukie Kawamura ◽  
Yukie Yonehara ◽  
Takashi Matsuo ◽  
Ichiro Iwamoto ◽  
...  

2020 ◽  
Vol 138 ◽  
pp. S81
Author(s):  
C. Blomqvist ◽  
L. Vehmanen ◽  
H. Sievänen ◽  
P. Kellokumpu-Lehtinen ◽  
R. Nikander ◽  
...  

2017 ◽  
Vol 13 (5) ◽  
pp. e505-e515 ◽  
Author(s):  
Jamie Stratton ◽  
Xin Hu ◽  
Pamela R. Soulos ◽  
Amy J. Davidoff ◽  
Lajos Pusztai ◽  
...  

Purpose: In postmenopausal women with breast cancer treated with aromatase inhibitors (AIs), most expert panels advise baseline bone mineral density testing with a dual-energy x-ray absorptiometry (DXA) scan repeated every 1 to 2 years. How often this recommendation is followed is unclear. Methods: We performed a retrospective analysis of women with stage I to III breast cancer who started AI therapy from January 1, 2008, to December 31, 2010, with follow-up through December 31, 2012, by using the SEER-Medicare database. Selection criteria included AI use for ≥ 6 months and no recent osteoporosis diagnosis or bisphosphonate use. We used multivariable logistic regression to investigate associations between patient characteristics and receipt of a baseline DXA scan. In patients who continued AI treatment, we assessed rates of follow-up scans. Results: In the sample of 2,409 patients (median age, 74 years), 51.0% received a baseline DXA scan. Demographic characteristics associated with the absence of a baseline DXA scan were older age (85 to 94 years v 67 to 69 years; odds ratio [OR], 0.62; 95% CI, 0.42 to 0.92) and black v white race (OR, 0.68; 95% CI, 0.47 to 0.97). Among patients who underwent a baseline DXA scan and continued AI for 3 years, 28.0% had a repeat DXA scan within 2 years and 65.9% within 3 years. In aggregate, of the 1,164 patients who continued with AI treatment for 3 years, only 34.5% had both a baseline and at least one DXA scan during the 3-year follow-up period. Conclusion: The majority of older Medicare beneficiaries with breast cancer treated with AIs do not undergo appropriate bone mineral density evaluation.


Sign in / Sign up

Export Citation Format

Share Document